Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Benralizumab for Bullous Pemphigoid
Recruiting1 awardPhase 3
Saint Louis, Missouri
This trial is testing benralizumab to see if it helps elderly patients with Bullous Pemphigoid, a rare skin disease. The medication aims to reduce inflammation by targeting specific immune cells. Benralizumab works by reducing the number of certain immune cells called eosinophils.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service